Three structures. One platform. Deal-ready.

Select the structure that fits your mandate

Full Platform Acquisition

White-Label OEM License

Strategic Co-Development

Complete transfer of the optical CGM platform — hardware IP, clinical data packages, regulatory filings, and manufacturing know-how. Zero-replacement architecture transfers intact.

License the optical engine under your brand. OEM partners own a perpetual hardware margin — no recurring sensor supply dependency, no 14-day replacement cycle in the cost model.

Joint development with GluTronics retaining core optical and clinical IP. Co-development partners gain FTO coverage and shared regulatory pathway access.

Suited for Big Tech and medical device companies seeking full first-party ownership of a no-consumable sensor platform.

Ideal for device integrators and consumer electronics platforms adding clinical-grade glucose data as a first-party feature.

Structured for partners targeting specific therapeutic verticals or regional regulatory approvals requiring a co-authoring position.

NDA and clinical data package delivery

Mutual NDA executed within 48 hours. Full clinical accuracy data, IP landscape summary, and FTO opinion delivered to corporate development counsel.

NDA to term-sheet in under 90 days.

Technical and regulatory due diligence

On-site hardware review, ISF lag elimination demonstration, and regulatory pathway walkthrough with GluTronics clinical and engineering leads.

The engagement process is as engineered as the platform. Each stage has defined deliverables, responsible parties, and a fixed clock.

Structure selection and term-sheet execution

Engagement model confirmed. Term-sheet drafted, negotiated, and executed. Transition or license commencement planning begins immediately.

Scope your engagement before the next board cycle.

Corporate development teams with active mandates are prioritized. Bring your NDA — we will bring the data package.